Search results
Results from the WOW.Com Content Network
Anemia frequently complicates the course of cancer. While anemia may be a presenting sign of malignancy, it may also be a consequence of a patient's antineoplastic therapy or progressive disease. Fatigue ranks as the most common symptom affecting cancer patients and limiting their daily activity.
We summarize clinical trial data affirming the safety and efficacy of currently available IV iron products used to treat cancer-associated anemia and illustrate how we use commonly available laboratory tests to assess iron status during routine patient management.
Depending on tumor type and stage, the prevalence of anemia is 31–50% in untreated solid tumors; the prevalence is even higher in hematologic neoplasms [37]. Anemia is also unfavorable for the course and therapy of malignant disease and of survival [14, 28, 29, 33, 39, 48].
This chapter reviews the mechanisms resulting in anemia in inflammation, including cancer, and focuses on the controversies around management with the ESAs and the adjuvant use of iron in anemia management.
Anemia and cancer often occur together. Anemia can be a cancer symptom or side effect of treatment. Here's what to know about the link.
Anemia occurs when a patient has a low red blood cell count. Because the body isn’t getting all the oxygen it needs, the patient is left feeling weak and fatigued. Other symptoms include. a pale complexion; shortness of breath; chest pain and headaches. Doctors diagnose anemia by evaluating a patient for these symptoms along with blood tests.
Cancer-induced anemia and anemia of chronic disease result from multiple causes and the fine interplay of pro- and antiapoptotic factors inducing a fine-tuned selective differentiation of the trilineage committed hematopoietic stem cell.